Advertisement
Advertisement
U.S. Markets open in 7 hrs 27 mins
Advertisement
Advertisement
Advertisement
Advertisement

GT Biopharma, Inc. (GTBP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.8600+0.0100 (+0.54%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8500
Open1.8200
Bid0.0000 x 800
Ask0.0000 x 900
Day's Range1.8000 - 1.9100
52 Week Range1.5100 - 7.4800
Volume71,783
Avg. Volume111,907
Market Cap56.883M
Beta (5Y Monthly)0.49
PE Ratio (TTM)N/A
EPS (TTM)-6.4530
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
  • GlobeNewswire

    GT Biopharma Announces Adjournment of Special Shareholders Meeting

    - Meeting adjourned to October 10, 2022 at 11 a.m. PST- GTB encourages all stockholders of record on August 8, 2022 who have not yet voted- to do so by 11:59 p.m. PST Time on October 9, 2022 BRISBANE, CALIFORNIA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced that

  • GlobeNewswire

    GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

    GTB-5550 generates a robust and NK cell specific proliferation signal compared to IL-15 aloneGTB-5550 specifically targets B7-H3+ cellsGTB-5550 effectively induced NK cell degranulation and interferon gamma production in response to various prostate, brain tumor (atypical rhabdoid/teratoid), HNSCC, multiple myeloma, sarcoma, ovarian, and myeloid malignanciesGTB-5550 TriKE In vivo activity in xenogeneic models of human tumor is underway and already validating in vitro studies BRISBANE, Calif., Se

  • GlobeNewswire

    GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

    BRISBANE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that management will present in-person at H.C. Wainwright’s 24th Annual Global Investment Conference taking place September 12-14, 2022 at the Lotte New York Palace. Company management will also be participating in 1x1 meet

Advertisement
Advertisement